Comparative efficacy of triptans for the abortive treatment of migraine: A multiple treatment comparison meta-analysis

Cephalalgia

Volumn 34, Issue 4, 2014, Pages 258-267

  Thorlund, Kristian ^a,b   Mills, Edward J ^b,c   Wu, Ping ^c   Ramos, Elodie ^d   Chatterjee, Anjan ^d   Druyts, Eric ^c   Goadsby, Peter J ^e  

^a MCMASTER UNIVERSITY   (Canada)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

^d Pfizer Ltd   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

headache; meta analysis; Migraine; multiple treatment comparison; pain free response; sustained response; triptans

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ANALGESIA; ARTICLE; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; FOLLOW UP; HEADACHE; HUMAN; META ANALYSIS; MIGRAINE; MULTIPLE TREATMENT COMPARISON; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

HEADACHE; META-ANALYSIS; MIGRAINE; MULTIPLE TREATMENT COMPARISON; PAIN-FREE RESPONSE; SUSTAINED RESPONSE; TRIPTANS;

ANALGESICS; BAYES THEOREM; HUMANS; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRYPTAMINES;

EID: 84896477648     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102413508661     Document Type: Article

References (29)

1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med. 2002 ; 346: 257-270
2. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992 ; 267: 64-69
3. Andlin-Sobocki P, Jonsson B, Wittchen HU, et al. Cost of disorders of the brain in Europe. Eur J Neurol. 2005 ; 12: 1-27
4. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003 ; 290: 2443-2454
5. The International Classification of Headache Disorders: Second edition. Cephalalgia. 2004 ; 24: 9-160
6. Stewart WF, Lipton RB, Liberman J. Variation in migraine prevalence by race. Neurology. 1996 ; 47: 52-59
7. Lipton RB, Hemelsky SW, Kolodner KN, et al. Migraine, quality of life and depression: A population-based case-control study. Neurology. 2000 ; 55: 629-635
8. Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: Results from the International Burden of Migraine Study (IBMS). Headache. 2011 ; 51: 1058-1077
9. Goadsby PJ, Sprenger T. Current practice and future directions in management of migraine: Acute and preventive. Lancet Neurol. 2010 ; 9: 285-298
10. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol. 2009 ; 16: 968-981
11. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 ; 78: 1337-1345
12. Goadsby PJ. The pharmacology of headache. Prog Neurobiol. 2000 ; 62: 509-525
13. Akerman S, Holland P, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011 ; 12: 570-584
14. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet. 2001 ; 358: 1668-1675
15. Mills EJ, Ioannidis JP, Thorlund K, et al. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA. 2012 ; 308: 1246-1253
16. Mills EJ, Bansback N, Ghement I, et al. Multiple treatment comparison meta-analyses: A step forward into complexity. Clin Epidemiol. 2011 ; 3: 193-202
17. Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators. Cephalalgia. 2012 ; 32: 6-38
18. Cramer H Mathematical methods of statistics. Princeton: Princeton University Press ; 1946: 282-282.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 ; 7: 177-188
20. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003 ; 327: 557-560
21. Salanti G, Kavvoura FK, Ioannidis JP. Exploring the geometry of treatment networks. Ann Intern Med. 2008 ; 148: 544-553
22. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004 ; 23: 3105-3124
23. Salanti G, Dias S, Welton NJ, et al. Evaluating novel agent effects in multiple-treatments meta-regression. Stat Med. 2010 ; 29: 2369-2383
24. Lu G, Ades A. Modeling between-trial variance structure in mixed treatment comparisons. Biostatistics. 2009 ; 10: 792-805
25. Lu G, Ades AE, Sutton AJ, et al. Meta-analysis of mixed treatment comparisons at multiple follow-up times. Stat Med. 2007 ; 26: 3681-3699
26. Tfelt-Hansen PC. Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: A review based on the GSK Trial Register. J Headache Pain. 2011 ; 12: 399-403
27. Tfelt-Hansen P. A review of evidence-based medicine and meta-analytic reviews in migraine. Cephalalgia. 2006 ; 26: 1265-1274
28. Tfelt-Hansen PC. Unpublished clinical trials with sumatriptan. Lancet. 2009 ; 374: 1501-1502
29. Pascual J, Mateos V, Roig C, et al. Marketed oral triptans in the acute treatment of migraine: A systematic review on efficacy and tolerability. Headache. 2007 ; 47: 1152-1168